Your browser is no longer supported. Please, upgrade your browser.
CRSP CRISPR Therapeutics AG daily Stock Chart
CRISPR Therapeutics AG
Index- P/E- EPS (ttm)-3.43 Insider Own2.20% Shs Outstand51.91M Perf Week-3.33%
Market Cap1.88B Forward P/E- EPS next Y-4.21 Insider Trans-11.06% Shs Float31.07M Perf Month-2.26%
Income-165.00M PEG- EPS next Q-0.88 Inst Own43.30% Short Float16.77% Perf Quarter1.06%
Sales3.10M P/S607.18 EPS this Y-101.60% Inst Trans0.01% Short Ratio6.92 Perf Half Y-8.43%
Book/sh7.58 P/B4.78 EPS next Y-10.20% ROA-38.00% Target Price55.94 Perf Year-31.87%
Cash/sh8.80 P/C4.12 EPS next 5Y- ROE-48.30% 52W Range22.22 - 73.90 Perf YTD26.92%
Dividend- P/FCF- EPS past 5Y- ROI-40.70% 52W High-50.93% Beta-
Dividend %- Quick Ratio16.80 Sales past 5Y- Gross Margin- 52W Low63.19% ATR1.88
Employees188 Current Ratio16.80 Sales Q/Q-99.70% Oper. Margin- RSI (14)48.64 Volatility6.20% 4.89%
OptionableYes Debt/Eq0.00 EPS Q/Q- Profit Margin- Rel Volume0.70 Prev Close36.43
ShortableYes LT Debt/Eq0.00 EarningsMar 14 Payout- Avg Volume752.96K Price36.26
Recom2.50 SMA20-1.83% SMA500.39% SMA200-10.36% Volume530,367 Change-0.47%
Apr-12-19Initiated Evercore ISI Outperform
Mar-14-19Initiated William Blair Mkt Perform
Jan-28-19Downgrade Goldman Buy → Neutral
Jan-22-19Downgrade Citigroup Neutral → Sell
Nov-30-18Initiated Needham Buy $62
Oct-10-18Initiated Wells Fargo Outperform $65
Oct-10-18Initiated Guggenheim Neutral
Sep-21-18Initiated Raymond James Underperform
May-15-18Reiterated Chardan Capital Markets Buy $25 → $72.50
Apr-06-18Initiated Goldman Buy $86
Mar-08-18Initiated JMP Securities Mkt Outperform $69
Jan-23-18Upgrade SunTrust Hold → Buy
Dec-22-17Initiated Piper Jaffray Overweight
Jul-14-17Initiated SunTrust Hold $16
Mar-28-17Initiated Chardan Capital Markets Buy $23.50
Apr-17-19 01:10PM  One-Size-Fits-All CRISPR Lock Could Catapult the Sector Forward -6.78%
07:14AM  Vertex, CRISPR's Gene Editing Drug Gets FDA's Fast Track Tag Zacks
Apr-16-19 02:18PM  CRISPR Therapeutics Attempts Breakout on FDA Fast Track Investopedia +5.20%
11:19AM  UPenn Treats First Cancer Patients in Crispr-Based Trial Bloomberg
07:00AM  CRISPR Therapeutics and Vertex Announce FDA Fast Track Designation for CTX001 for the Treatment of Beta Thalassemia GlobeNewswire
Apr-15-19 02:00PM  Four Companies Could Power The New Genomics ETF ETF Trends
Apr-03-19 09:15AM  Stocks Hold Onto Gains in Quiet Session Zacks
Apr-01-19 07:00AM  CRISPR Therapeutics to Participate in Upcoming Investor Conferences GlobeNewswire
Mar-28-19 08:19AM  Better Buy: CRISPR Therapeutics vs. Sangamo Therapeutics Motley Fool
Mar-27-19 01:13PM  8 Genomic Testing Stocks That Can Ease the Sting of Theranos InvestorPlace
Mar-26-19 06:07PM  3 Top Small-Cap Stocks to Buy Right Now Motley Fool
Mar-21-19 06:13AM  Should You Buy Bio-Path Stock After 5-Fold Gain? 3 Pros, 3 Cons InvestorPlace
06:00AM  CRISPR and Vertex- Front-Runners in Gene-Therapy MoneyShow
Mar-07-19 02:47PM  5 Top Gene-Editing Stocks for 2019 Motley Fool
10:49AM  Has CRISPR Therapeutics AG (NASDAQ:CRSP) Got Enough Cash? Simply Wall St.
Mar-06-19 07:00AM  CRISPR Therapeutics to Participate in Upcoming Investor Conferences GlobeNewswire -6.07%
Mar-04-19 11:36AM  Why NOW Is the Time to Buy Gene Therapy Stocks InvestorPlace
09:15AM  S&P Reclaims 2800; NASDAQs Streak Hits 10 Weeks Zacks
Feb-27-19 04:53PM  CRISPR Therapeutics Announces Presentations at the American Association for Cancer Research 2019 Annual Meeting GlobeNewswire
09:58AM  CRISPR Therapeutics Rallies as Gene Stocks Get Hot Again InvestorPlace
Feb-26-19 11:15AM  Biotech ETFs Jump on Roche-Spark Deal Zacks -8.70%
10:54AM  CRISPR Therapeutics Up as Dosing Starts in Thalassemia Study Zacks
09:15AM  Deal on the Way Now that Deadline is Delayed? Zacks
Feb-25-19 04:31PM  Why Danaher, CRISPR Therapeutics, and Clementia Pharmaceuticals Jumped Today Motley Fool +25.20%
04:12PM  Biotech Stocks Pop After This Company Used CRISPR Drug In A Patient Investor's Business Daily
02:21PM  Here's Why Gene Therapy Stocks Are Soaring Today Motley Fool
10:11AM  Crispr Infuses First Human in Landmark Gene-Editing Study Bloomberg
08:02AM  CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2018 Financial Results GlobeNewswire
08:00AM  CRISPR Therapeutics and Vertex Announce Progress in Clinical Development Programs for the Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001 GlobeNewswire
12:58AM  [$$] Crispr Therapeutics treats its first human with gene editing Financial Times
Feb-23-19 09:15AM  Strong Friday Close Secures a 9th Week in the Green Zacks
Feb-21-19 07:00AM  CRISPR Therapeutics Proposes New Members to the Board of Directors GlobeNewswire
Feb-19-19 07:00AM  CRISPR Therapeutics and StrideBio Expand Exclusive Development and Option Agreement GlobeNewswire
Feb-14-19 12:01PM  Is Moderna a Buy? Motley Fool
Feb-12-19 07:49AM  Jim Cramer Gives His Opinion On Cronos, Etsy And More Benzinga
Feb-11-19 12:36PM  Here's Why CRISPR Therapeutics Rose 13.5% in January Motley Fool
Feb-09-19 10:03AM  Should Sangamo's Failure Make CRISPR Investors Nervous? Motley Fool
Feb-07-19 03:33PM  Vertex Pharmaceuticals: New Drug, Same Great Growth Story Motley Fool -8.73%
Feb-06-19 10:31AM  Vertex (VRTX) Q4 Earnings Beat on Solid CF Products Sales Zacks
Feb-05-19 06:00AM  Why Even a Pessimistic Analyst Thinks CRISPR Therapeutics Will Jump 20% Motley Fool
Feb-03-19 02:04PM  3 Gene Therapy Stocks With Huge Catalysts in 2019 Motley Fool
Feb-01-19 01:53PM  3 Biotech Stocks That Are Set for a Breakthrough InvestorPlace
Jan-30-19 10:02AM  Is a Beat in Store for Vertex (VRTX) This Earnings Season? Zacks
Jan-28-19 04:16PM  CRISPR Stocks Flattened After 1 Downgraded Amid Steep Rivalry Investor's Business Daily -6.11%
09:33AM  Goldman Sachs Steps To The Sidelines On Crispr Therapeutics Benzinga
Jan-24-19 10:46AM  Vertex Terminates COO Ian Smith on Code of Conduct Violation Zacks
Jan-23-19 08:18AM  Better Buy: CRISPR Therapeutics vs. Editas Medicine Motley Fool -5.08%
Jan-22-19 06:55PM  Should You Sell CRISPR Therapeutics Following an Analyst Downgrade? Motley Fool -10.91%
11:50AM  Here's Why CRISPR Therapeutics Stock Fell Today Motley Fool
07:00AM  CRISPR Therapeutics and ProBioGen Sign Collaboration and License Agreement to Develop Novel In Vivo Delivery Technologies GlobeNewswire
Jan-19-19 05:55PM  Could CRISPR Therapeutics Be a Millionaire-Maker Stock? Motley Fool
Jan-18-19 12:55PM  4 Gene-Editing Technologies That Could Replace CRISPR Motley Fool
Jan-12-19 12:00PM  Where Will CRISPR Therapeutics Be in 10 Years? Motley Fool
Jan-11-19 04:14PM  Why This IBD Stock Of The Day Broke Out Despite Biotech Turbulence Investor's Business Daily
Jan-10-19 03:36PM  The Best CRISPR Stock Gained 21% in 2018, While The Worst Lost 29% Motley Fool -5.88%
08:15AM  4 Reasons Editas Medicine's Future Looks Really Bright Motley Fool
Jan-09-19 11:21AM  CRISPR cadre: Check out the 12 Mass. companies exploring gene editing American City Business Journals +8.00%
09:15AM  Market's Newfound Optimism Brings Another 1% Gain Zacks
Jan-07-19 10:03AM  Vertex, CRISPR's Sickle Disease Drug Gets FDA's Fast Track Tag Zacks +13.05%
08:23AM  Here's Why CRISPR Therapeutics Tanked 25.5% in December Motley Fool
Jan-06-19 09:09AM  Better Buy: CRISPR Therapeutics vs. Vertex Pharmaceuticals Motley Fool
Jan-04-19 05:11PM  What Happened in the Stock Market Today Motley Fool +8.03%
04:24PM  These Stocks Pop After FDA Expedites Review Of Gene-Editing Therapy Investor's Business Daily
07:00AM  CRISPR Therapeutics and Vertex Announce FDA Fast Track Designation for CTX001 for the Treatment of Sickle Cell Disease GlobeNewswire
Jan-03-19 10:33AM  Vertex teams up with Feng Zhang startup on gene editing tech American City Business Journals -6.19%
Dec-31-18 11:42AM  Dow Rises 91 Points Because Everybodys Ready for a New Year +6.80%
Dec-27-18 12:27PM  3 Gene Therapy Stocks to Play Biotechs Future InvestorPlace
09:15AM  Christmas Comes a Day Late Zacks
Dec-24-18 09:37AM  Don't Miss Chinese Biotechs Motley Fool +7.44%
Dec-21-18 11:25AM  Did Chinas Designer Babies Just Open Pandoras Box? Motley Fool -17.10%
Dec-19-18 10:55PM  Is CRISPR Therapeutics AG (CRSP) Going to Burn These Hedge Funds? Insider Monkey
09:12AM  Vertex's (VRTX) 3rd Study on Pain Drug Meets Primary Endpoint Zacks
05:37AM  Waltham's Eloxx aims to reach cystic fibrosis patients that Vertex can't American City Business Journals
Dec-18-18 09:35AM  Gene-Editing Stocks Took Stutter Steps Forward in 2018 Motley Fool -6.46%
09:10AM  Under Armour Tanks on Guidance Motley Fool
Dec-16-18 09:07AM  2 Sets of Disasters Biotech Will Pay For in 2019 Motley Fool
Dec-13-18 01:04PM  3 High-Growth Stocks That Are Just Getting Started Motley Fool -8.08%
10:13AM  Top 10 Healthcare Stories of 2018 Motley Fool
Dec-10-18 04:31PM  Why CRSP Stock Has Added Layers of Risk InvestorPlace
12:54PM  Here's Why Crispr Therapeutics Rose 17% in November Motley Fool
12:42PM  Here's Why Editas Medicine Jumped 23% in November Motley Fool
Dec-01-18 11:24AM  Genetic editing is this week's champ Fed's Powell is the chump Yahoo Finance
Nov-30-18 05:45PM  CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: What You Should Know Zacks
04:14PM  This Biotech Stock Could Launch Its First CRISPR Drug In 2022 Investor's Business Daily
10:31AM  Why Crispr Therapeutics Stock Is Up By 65% So Far in 2018 Motley Fool
Nov-26-18 04:22PM  With genetically edited babies, a scientist transgresses a moral boundary MarketWatch
02:46PM  Mass. biotech leaders voice alarm over report of first gene-edited babies American City Business Journals
Nov-21-18 07:00AM  CRISPR Therapeutics to Participate in Upcoming Investor Conferences GlobeNewswire +7.12%
Nov-18-18 04:51PM  Better Buy: CRISPR Therapeutics AG vs. Sangamo Therapeutics Inc. Motley Fool
Nov-13-18 08:45AM  New Research Coverage Highlights CAS Medical, Saia, Core Laboratories N.V, Perceptron, CRISPR Therapeutics AG, and IEC Electronics Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire
Nov-12-18 05:50PM  CRISPR Therapeutics AG (CRSP) Stock Moves -0.55%: What You Should Know Zacks
11:51AM  3 DNA Stocks That Are on the Uptrend InvestorPlace
Nov-09-18 07:00AM  CRISPR Therapeutics and MaxCyte Expand Clinical and Commercial License Agreement into Oncology GlobeNewswire
Nov-07-18 07:46PM  Cambridge's Editas asks FDA to start gene editing trial American City Business Journals +10.81%
04:33PM  CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2018 Financial Results GlobeNewswire
Nov-05-18 02:13PM  Here's Why CRISPR Stocks Fell as Much as 40.7% in October Motley Fool
09:35AM  ImmunoGen (IMGN) Beats on Earnings in Q3, Lowers Guidance Zacks
07:55AM  5 Drug/Biotech Stocks Set to Trump Estimates in Q3 Earnings Zacks
Nov-02-18 11:31AM  VIVUS (VVUS) Q3 Loss Narrower Than Expected, Revenues Up Y/Y Zacks
09:15AM  Geron's (GERN) Q3 Earnings Beat, Revenues Miss, Shares Down Zacks
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. The company is also developing CTX110, a donor-derived gene-edited allogeneic CAR-T therapy targeting cluster of differentiation 19 positive malignancies. In addition, it is developing allogeneic CAR-T programs targeting B-Cell maturation antigen and CD70; CTX120, a CAR-T cell product candidate for the treatment of multiple myeloma; CTX130 for the treatment of solid tumors and hematologic malignancies; programs to treat Hurler Syndrome and severe combined immunodeficiency disease, as well as glycogen storage disease Ia; and programs targeting diseases, such as Duchenne muscular dystrophy and cystic fibrosis. It has a collaboration agreements with Vertex Pharmaceuticals, Incorporated and Vertex Pharmaceuticals (Europe) Limited to develop, manufacture, commercialize, sell, and use various therapeutics; and StrideBio LLC to develop adeno-associated viral capsids. The company also has research collaboration agreements with Neon Therapeutics for developing neoantigen-based therapeutic vaccines and T cell therapies; Massachusetts General Hospital Cancer Center to develop T cell therapies for cancer; ViaCyte, Inc. for designing, developing, and commercializing gene-edited allogeneic stem cell therapies for the treatment of diabetes; and ProBioGen AG to develop novel in vivo delivery modalities for CRISPR/Cas9. CRISPR Therapeutics AG is headquartered in Zug, Switzerland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Novak RodgerPresidentMar 04Sale40.4576,5273,095,240948,007Mar 05 05:59 PM
Novak RodgerPresidentMar 01Sale40.018,693347,7961,024,534Mar 05 05:59 PM
Novak RodgerPresidentFeb 25Sale40.0014,780591,2331,033,227Feb 27 04:10 PM
Novak RodgerPresidentJan 09Sale35.0182,6902,894,9771,048,007Jan 10 04:09 PM
Novak RodgerPresidentJan 08Sale35.0917,310607,4081,130,697Jan 10 04:09 PM
Vertex Pharmaceuticals (Europe10% OwnerDec 27Buy24.9527,461685,1165,380,940Dec 28 04:34 PM
Vertex Pharmaceuticals (Europe10% OwnerDec 26Buy24.8912,737317,0775,353,479Dec 28 04:34 PM
Vertex Pharmaceuticals (Europe10% OwnerDec 24Buy24.5868,0001,671,4825,340,742Dec 26 04:35 PM
Vertex Pharmaceuticals (Europe10% OwnerDec 21Buy22.5822,742513,4785,272,742Dec 26 04:35 PM
EMSTER KURT VONDirectorDec 18Sale29.7069,9252,077,1011,164,268Dec 19 04:22 PM
EMSTER KURT VONDirectorDec 17Sale33.173,00999,7971,234,193Dec 19 04:22 PM
Kulkarni SamarthChief Executive OfficerDec 07Option Exercise1.8121,50038,915167,290Dec 11 04:29 PM
CELGENE CORP /DE/10% OwnerNov 21Sale19.2580,0001,540,0004,173,019Dec 07 09:57 AM
CAGNONI PABLO JDirectorJul 05Option Exercise5.591,6849,4141,684Jul 05 06:25 PM
CAGNONI PABLO JDirectorJul 05Sale62.001,684104,4080Jul 05 06:25 PM
CAGNONI PABLO JDirectorJul 03Option Exercise5.595,81632,5115,816Jul 05 06:25 PM
CAGNONI PABLO JDirectorJul 03Sale62.005,816360,5920Jul 05 06:25 PM
EMSTER KURT VONDirectorJun 05Sale12.5192011,50918,316Jun 07 04:36 PM
Kulkarni SamarthChief Executive OfficerJun 01Option Exercise1.8115,00027,150163,560Jun 05 08:20 PM
Kulkarni SamarthChief Executive OfficerJun 01Sale69.3615,0001,040,400148,560Jun 05 08:20 PM
Novak RodgerPresidentMay 17Option Exercise8.2775,000620,4241,223,007May 21 04:54 PM
Novak RodgerPresidentMay 17Sale60.0075,0004,500,0001,148,007May 21 04:54 PM
Bolzon Bradley J PhDDirectorMay 15Sale57.9944,0002,551,440640,014May 17 05:15 PM
Woiwode ThomasDirectorMay 15Sale57.9944,0002,551,440640,014May 17 05:11 PM
EMSTER KURT VONDirectorMay 14Sale55.36400,00022,142,5561,237,202May 15 08:04 PM
EMSTER KURT VONDirectorMay 11Sale52.84250,00013,209,9001,637,202May 15 08:04 PM
Woiwode ThomasDirectorMay 08Sale51.451,65385,0475,629May 09 05:15 PM
Bolzon Bradley J PhDDirectorMay 08Sale50.549,241467,06734,745May 09 05:14 PM
Bolzon Bradley J PhDDirectorMay 07Sale50.38119,7096,030,82634,977May 09 05:14 PM
Woiwode ThomasDirectorMay 07Sale50.38119,7096,030,82634,977May 09 05:15 PM
Bolzon Bradley J PhDDirectorApr 30Sale50.2930,5661,537,13838,064May 02 06:00 PM
Woiwode ThomasDirectorApr 30Sale50.2930,5661,537,13838,064May 02 06:00 PM
Bolzon Bradley J PhDDirectorApr 27Sale50.0211,648582,65538,852Apr 30 08:58 PM
Woiwode ThomasDirectorApr 27Sale50.0211,648582,65538,852Apr 30 08:57 PM
Woiwode ThomasDirectorApr 26Sale50.11210,61010,553,78239,152Apr 30 08:57 PM
Bolzon Bradley J PhDDirectorApr 26Sale50.11210,61010,553,78239,152Apr 30 08:58 PM
Woiwode ThomasDirectorApr 24Sale50.9922,8411,164,65544,582Apr 26 05:01 PM
Bolzon Bradley J PhDDirectorApr 24Sale50.9922,8411,164,65544,582Apr 26 04:57 PM
Versant Venture Capital V, L.P10% OwnerApr 24Sale50.9922,8411,164,65544,582Apr 26 04:44 PM
Versant Venture Capital IV, L.10% OwnerApr 23Sale50.68101,9945,168,90145,171Apr 24 07:44 PM
Woiwode ThomasDirectorApr 23Sale50.68101,9945,168,90145,171Apr 24 07:42 PM
Bolzon Bradley J PhDDirectorApr 23Sale50.68101,9945,168,90145,171Apr 24 07:41 PM